Clinical trials: Non-Alcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic Steatohepatitis, Ultrasound
Innovative Liver Elasticity, Attenuation, and Dispersion Ultrasound Study
The objective of this study is: (1) to investigate the correlation of ultrasound parameters (SW speed, Dispersion slope, Attenuation value, Normalized Local Variance, Liver / Kidney Intensity Ratio) with the pathological…
- Conditions
- Nonalcoholic Steatohepatitis, Ultrasound, Elastography
- Trial name
- iLEAD (NCT04012242)
- Testing
- Ultrasound application
- Where
- 18 sites in United States, China and 6 more
- Volunteers
- 400 people
- Sponsor
- Tokyo Medical University
Morbid Obesity, Non Alcoholic Steatohepatitis
Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients
Abstract: Fatty liver most frequently corresponds to a fat overload of the liver. It is usually classified as alcoholic steatosis or non-alcoholic steatosis.
- Trial name
- FIRM (NCT01695083)
- Where
- France
- Volunteers
- 186 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-Alcoholic Fatty Liver Disease
Ursodeoxycholic Acid in Patients With NAFLD - Clinical Observation
Patients with NAFLD indicated for ursodeoxycholic acid treatment ("by SPC: cholestatic hepatitis") will be offered an observational study. Examinations will be performed before the treatment and after 6month period.
- Trial name
- URSO (NCT05256979)
- Where
- Czechia
- Volunteers
- 20 people
- Sponsor
- General University Hospital, Prague
Non-Alcoholic Fatty Liver Disease
Dynamic Changes and Risk Factors of Fibrosis and Steatosis Progression in Nonalcoholic Fatty Liver Disease
It is an observational study of non alcoholic fatty liver disease (NAFLD) patients with a calculated sample size of 500. Liver biopsy proved NAFLD patients will be recruited in this study for 10 years follow-up.
- Trial name
- NCT03635541
- Testing
- observational group of NAFLD
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Beijing Friendship Hospital
Non-alcoholic Steatohepatitis
Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants
This is a single-center, randomized, double-blind, placebo-controlled Phase I clinical study, divided into two parts. The first part is a single-dose escalation study (Part1,SAD study phase), and the second part is a…
- Trial name
- NCT06716905
- Testing
- ACT500 tablets
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Non-Alcoholic Fatty Liver Disease
Effect of Modified Time-restricted Feeding in Preventing Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).
The purpose of the study is to examine the effects of modified time-restricted feeding and conventional dietary approaches in motivated obese fatty liver patients on biochemical markers, imaging studies, and anthropometric…
- Trial name
- NCT03848390
- Testing
- Conventional diet, Modified Time-restricted Feeding, Physical activity
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The University of Texas Health Science Center, Houston
NAFLD, PCOS
Bicalutamide Therapy in Young Women With NAFLD and PCOS
Nonalcoholic steatohepatitis (NASH), or fat-related liver inflammation and scarring is projected to be the leading cause of cirrhosis in the United States (U.S.) within the next few years.
- Trial name
- NCT05979389
- Testing
- Bicalutamide 50 mg
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Nonalcoholic Steatohepatitis
Pentoxifylline in Patients With Nonalcoholic Steatohepatitis
One third of the population in the United States has nonalcoholic fatty liver disease (NAFLD). Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, can lead to cirrhosis.Currently, there is no proven therapy for…
- Trial name
- NCT00590161
- Testing
- pentoxifylline (PTX)
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Case Western Reserve University
Hepatic Impairment, Healthy Volunteers
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma PK of PF-06865571.
- Trial name
- NCT04091061
- Testing
- PF-06865571 100 mg
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
NASH, NAFLD
Phase Ib/II Study to Evaluate the Efficacy and Safety of GH509 Versus Placebo in Patients With NASH/NAFLD
This is a Phase Ib/II, randomized, double-blind, placebo-controlled, international multi-center clinical study to investigate the efficacy and safety of GH509 in subjects with NASH/NAFLD
- Trial name
- NCT05784779
- Testing
- GH509
- Where
- China
- Volunteers
- 180 people
- Sponsor
- 1Globe Biomedical Co., Ltd.
Non-Alcoholic Fatty Liver Disease
Lifestyle Guidance Methods in NAFLD
To determine the efficiency of lifestyle modification (due to a dietitian or digital application) compared to standard of care.
- Trial name
- INDIANA (NCT05792488)
- Testing
- Coach, App, Standard of care
- Where
- Belgium
- Volunteers
- 300 people
- Sponsor
- Ziekenhuis Oost-Limburg
Nonalcoholic Fatty Liver Disease
Effectiveness of Endoscopic Sleeve Gastroplasty in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Endoscopic weight loss procedures, also termed endoscopic sleeve gastroplasty (ESG), has been proposed as a non-surgical procedure for managing obesity and offers a standard weight loss approach.
- Trial name
- NCT05507151
- Testing
- Endoscopic Sleeve Gastroplasty
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- West Virginia University
NASH - Nonalcoholic Steatohepatitis
A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH
The study includes 52 weeks, double-blind treatment period. Clinic visits will occur at Randomization and every four weeks from Week 4 through Week 52 and through End of Study period.
- Trial name
- VOYAGE (NCT04173065)
- Testing
- VK2809
- Where
- 79 sites in United States, Belgium and 3 more
- Volunteers
- 248 people
- Sponsor
- Viking Therapeutics, Inc.
Non-alcoholic Steatohepatitis
Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis
Silymarin, also known as milk thistle, is an alternative medicine commonly found in health food and vitamin stores. People with liver disease sometimes use silymarin because it is thought to have liver protecting effects…
- Trial name
- SyNCH (NCT00680407)
- Testing
- Silymarin 700 mg, Silymarin 420 mg
- Where
- 6 sites in United States
- Volunteers
- 78 people
- Sponsor
- Madaus Inc
Dyslipidemias, Non-Alcoholic Fatty Liver Disease
A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)
The main purpose of this study is to evaluate the safety and tolerability of LY3885125 after administration of single ascending doses in participants with dyslipidemia (part A) and multiple doses in participants with…
- Trial name
- NCT06007651
- Testing
- LY3885125
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Eli Lilly and Company
Insulin Resistance, Type2 Diabetes Mellitus
High-fat Overfeeding, Hepatokines and Appetite Regulation
The present study will investigate the effect of high-fat overfeeding on a group of liver-secreted proteins linked to worsened blood sugar control, as well as proteins involved in appetite control.
- Conditions
- Insulin Resistance, Type2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, Obesity
- Trial name
- OVEREAT (NCT03369145)
- Testing
- High-fat diet
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Loughborough University
Liver Diseases, Primary Biliary Cirrhosis
Repeatability and Reproducibility of Multiparametric MRI
This study aims to prospectively assess the repeatability and reproducibility of iron-corrected T1 (cT1), T2*, and hepatic proton density fat fraction (PDFF) quantification with multiparametric MRI using the LiverMultiScan™ (LMS…
- Conditions
- Liver Diseases, Primary Biliary Cirrhosis, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
- Trial name
- NCT03743272
- Testing
- LiverMultiScan
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Perspectum
Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH).
- Trial name
- NASHGEN-2 (NCT05519475)
- Testing
- ALN-HSD
- Where
- 71 sites in United States, Japan and 2 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Type 2 Diabetes, Non Alcholic Fatty Liver Disease
Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions ranging from liver steatosis (NAFL), steatohepatitis (NASH), advanced liver fibrosis and ultimately leads to cirrhosis in a significant proportion of…
- Trial name
- B-LIFT (NCT06035874)
- Testing
- Bempedoic acid
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Medanta, The Medicity, India
Obesity, Diabetes Mellitus
Characterization of the Microbiome in Peritoneum, Jejunum, Rectum and Stool
Characterization of the human microbiome in the jejunum and comparison to the microbiome in the rectum and stool in order to see how the microbial communities change within the intestines.
- Conditions
- Obesity, Diabetes Mellitus, Fatty Liver, Nonalcoholic, Leaky Gut Syndrome
- Trial name
- METABIOM (NCT04067440)
- Testing
- Microbial Swab
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Universität des Saarlandes
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.